会社概要
- 正式社名: Nanjing Hanxin Pharmaceutical Technology Co.,Ltd
- 登録国: China
- 住所: Building C5, No.9 Weidi Road, Xianlin Street, Qixia District, Nanjing, Jiangsu, China
- 設立年: 2021
説明:
Nanjing Hanxin Pharmaceutical Technology Co., Ltd, established in 2017, manufactures active pharmaceutical ingredients, digestive-system drugs, and peptides. The company was recognized as a Jiangsu Provincial Technology-Advanced Service Enterprise in 2019, obtained national-level intellectual property management system certification in 2020, acquired Nanjing Cuccess Pharmaceutical Co., Ltd. and earned National High-tech Enterprise status in 2021, and was designated a Jiangsu Provincial Specialized, Refined, Differential, and Innovative SME in 2022. Offering CRO, CMO, and CDMO contract manufacturing with OEM, ODM, and own-brand production, the company distributes to markets across North America, Central/South America, Western and Eastern Europe, Australasia, Asia, the Middle East, and Africa.
事業活動
原薬(API)
原薬メーカー製造業者
受託・アウトソーシングサービス
医薬品開発製造受託機関(CDMO)
販売市場
- Western Europe: Austria, Belgium, France
- Northern America: Bermuda, Canada, Greenland, Saint Pierre and Miquelon, United States
- Central America: Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama
- South America: Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Falkland Islands, French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela
主要製品/サービス
- 原薬(API): Semaglutide, PDRN, Earthworm Protein, Chondroitin sulfate oligosaccharides (LetopCS) ® ）, GABA（ γ- Aminobutyric acid, Ergothione, Acetic acid ganerik (chemical synthesis), Acetylated sodium hyaluronate, Cationic sodium hyaluronate, Chloroacetyl catechol, DeGu insulin side chain, Epinephrine (chemical synthesis), Liraglutide 31 peptide main chain, Liraglutide (recombinant), NmHA ® Nano sodium hyaluronate, Norepinephrine bitartrate (chemically synthesized), Recombinant CPB, Recombinant EK, Recombinant Kex II, Recombinant type III collagen protein, Smegglutide 29 peptide main chain, Smegglutide side chain
- 天然抽出物・生薬原料: Animal extracts
- 生物由来・発酵原料: Biological fermentation raw materials
- ATC分類(解剖治療化学分類): Insulin Aspart
当社の製品・サービス
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · ATC (Anatomical Therapeutic Chemical) Classification
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · Active Pharmaceutical Ingredients (APIs)
認証
FDA
GMP Formulation Facility
FDA- and GMP-compliant manufacturing site producing injectables
FDA inspections with zero Form 483 observations
FDA approval for oncology
評価
(0)
(0)
(0)
(0)
(0)
コメント
フィルター:
並べ替え:
コメントはありません。
評価とコメントを残す